Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the transaction, the insider directly owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Solomon Moshkevich also recently made the following trade(s):
- On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $305,900.28.
- On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90.
- On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00.
- On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00.
- On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68.
Natera Trading Up 21.4%
Shares of NASDAQ:NTRA opened at $322.10 on Friday. The company has a market cap of $46.13 billion, a price-to-earnings ratio of -236.84 and a beta of 1.51. Natera, Inc. has a 12 month low of $149.38 and a 12 month high of $323.01. The company has a 50-day moving average price of $254.03 and a 200 day moving average price of $223.79.
Institutional Trading of Natera
Hedge funds have recently bought and sold shares of the stock. Horizon Investments LLC increased its holdings in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC lifted its stake in Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. boosted its position in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after buying an additional 46 shares during the period. Parallel Advisors LLC boosted its position in shares of Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares during the period. Finally, First Horizon Corp grew its stake in shares of Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after buying an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Key Stories Impacting Natera
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
- Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
- Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
- Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
- Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
- Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
- Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone
Wall Street Analyst Weigh In
NTRA has been the subject of a number of recent analyst reports. Royal Bank Of Canada lifted their price target on shares of Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a research note on Friday. BTIG Research increased their price target on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Friday. Barclays restated an “overweight” rating and set a $340.00 price objective on shares of Natera in a report on Friday. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Natera in a research note on Monday, July 6th. Finally, Morgan Stanley upped their price target on shares of Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $299.65.
View Our Latest Stock Analysis on NTRA
Natera Company Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
